^
Association details:
| Biomarker: | ASPSCR1-TFE3 fusion +TMB-H |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
Published date:
05/06/2022
Excerpt:
In this study, we report data obtained from two STS patients...A 26 year-old female patient was diagnosed with ASPS. PD-L1 was negative. Next generation sequencing (NSG) revealed ASPSCR1-TFE3 fusion and TMB-H. Following eight months of anlotinib monotherapy, the patient's disease progressed but continued to benefit from subsequent use of anlotinib combined with toripalimab for 19 months.
DOI:
10.3389/fimmu.2022.832593
